|Bid||1,799.00 x 0|
|Ask||1,800.50 x 0|
|Day's range||1,774.50 - 1,807.00|
|52-week range||1,440.00 - 2,089.00|
|Beta (3Y monthly)||0.60|
|PE ratio (TTM)||15.40|
|Earnings date||9 Aug 2019|
|Forward dividend & yield||0.40 (2.22%)|
|1y target est||23.92|
Attractive stocks have exceptional fundamentals. In the case of Hikma Pharmaceuticals PLC (LON:HIK), there's is a...
Roland Head explains why he'd buy this former FTSE 100 (INDEXFTSE: UKX) stock, despite its recent demotion to the FTSE 250.
Every investor in Hikma Pharmaceuticals PLC (LON:HIK) should be aware of the most powerful shareholder groups...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Hikma Pharmaceuticals PLC (LON...
The opioid crisis in the United States is a medical and societal tragedy, but some companies are working to fight addiction.
The FTSE 100 was up 0.3 percent. The domestically-focused FTSE 250 was up 0.3 percent as investors waited for further Brexit developments with reports that Prime Minister Theresa May would ask the European Union to delay Brexit by at least three months. May's Brexit plans were derailed after the speaker of Britain's parliament said on Monday that her deal could not be voted on again after two thumping defeats unless a different proposal was submitted.
In December 2018, Hikma Pharmaceuticals PLC (LON:HIK) announced its latest earnings update, which showed that the company turned profitable again after experiencing negative earnings in the previous financial year. Below,Read More...
European shares jumped on Wednesday as investors bet British lawmakers would vote to reject a disorderly no-deal Brexit, but underwhelming results from Inditex and Adidas kept gains limited. Lawmakers resoundingly voted against Prime Minister Theresa May's amended Brexit deal late on Tuesday, forcing parliament to decide whether to back a no-deal Brexit or seek a last-minute delay to the process. "I think the market can see that today parliament is going to vote against no deal," said Duncan Weldon, cross asset allocation strategist at Legal & General Investment.
(Reuters) - Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent ...
Britain's main stock index clung on to last session's advance, aided by earnings-driven gains in AstraZeneca and Micro Focus, while medical device maker ConvaTec single-handedly contributed to nearly one-third of the midcap index's dip. The FTSE 100 added 0.1 percent, outperforming its U.S. and European peers, though the FTSE 250 was down 0.4 percent as ConvaTec tanked after reporting what its CEO called "disappointing results".
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small and large cap stocks are widelyRead More...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices